Eczema Pipeline Drugs Landscape Report 2025: MOA Analysis, R&D Progress, Clinical Trial Pipeline, and Strategic Market Evolution

DelveInsight's, "Eczema Pipeline Insight, 2025" report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Eczema pipeline landscape. It covers the Eczema pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Eczema pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Eczema Pipeline. Dive into DelveInsight's comprehensive report today! @ Eczema Pipeline Outlook [https://www.delveinsight.com/sample-request/eczema-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Eczema Pipeline Report

* On 17 November 2025, Inmagene LLC conducted a phase 2b study to assess the efficacy and safety profile of various dose regimens of IMG-007 in adult participants with moderate-to-severe active atopic dermatitis (AD) up to 52 weeks.
* On 14 November 2025, Celldex Therapeutics announced a phase 2 study to assess the efficacy and safety of barzolvolimab (CDX-0159) in adult participants with Atopic Dermatitis. There is a screening period of up to 28 days, a 16-week double-blind, placebo-controlled treatment period, a 16-week double-blind, active treatment period, and a 16-week follow-up period. On Day 1, participants will be randomly assigned on a 1:1:1 ratio to receive barzolvolimab (CDX-0159) by subcutaneous injections of 150 mg every 4 weeks (Q4W) after an initial loading dose of 450 mg [Arm 1], 300 mg Q4W after an initial loading dose of 450 mg [Arm 2], or placebo Q4W [Arm 3].
* On 10 November 2025, Aclaris Therapeutics Inc . initiated a study evaluates ATI-045 versus placebo in patients with Moderate-to-Severe Atopic Dermatitis.
* DelveInsight's Eczema pipeline report depicts a robust space with 100+ active players working to develop 100+ pipeline therapies for Eczema treatment.
* The leading Eczema Companies such as Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries, Brickell Biotech Inc., Dermira, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics , and others.
* Promising Eczema Pipeline Therapies such as alitretinoin, Arctiva, KY1005, Dupilumab, Lebrikizumab, Baricitinib, MEDI9929, Midazolam, Omeprazole , and others.

Stay ahead with the most recent pipeline outlook for Eczema. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Eczema Treatment Drugs [https://www.delveinsight.com/sample-request/eczema-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The Eczema Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Eczema Pipeline Report also highlights the unmet needs with respect to the Eczema.

Eczema Overview

Eczema, also known as atopic dermatitis, is the most common form of dermatitis. Genetic as well as environmental factors are thought to play a part in the pathogenesis. Eczema is most commonly seen in children but can be seen in adults. People with the disease tend to have dry, itchy skin that is prone to infection. Eczema is commonly known as the ""itch that rashes"" due to dry skin that leads to a rash as a result of scratching or rubbing. The most important treatment of eczema is skin hydration followed by topical steroids for flare-ups. The lifetime prevalence of atopic dermatitis is about 15-30% in children and 2-10% in adults.

Eczema Emerging Drugs Profile

* Amlitelimab: Kymab

Amlitelimab SAR445229 (formerly KY1005) is a human monoclonal antibody that targets OX40L, a key regulator of the immune system. Amlitelimab is designed to rebalance the immune system by blocking inappropriate activation and proliferation of 'pro-inflammatory' effector T cells and promoting expansion of 'anti-inflammatory' regulatory T cells, without broad suppression of the immune system. It is believed this mechanism-of-action means Amlitelimab could be applicable to a range of autoimmune and inflammatory diseases. In Phase I clinical trial in healthy volunteers, Amlitelimab was able to block T cell-driven skin inflammation while being well tolerated. It is believed the immune-modulating mechanism of Amlitelimab has broad potential therapeutic application in multiple diseases caused by immune dysregulation. Currently, the drug is being developed in the Phase II stage of clinical trial evaluation for the treatment of Eczema.

* BX 005: BiomX

BX005, a topical phage cocktail that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease. In preclinical in vitro studies, BX005 was shown to be active against over 90% of strains of S. aureus isolated from the skin of subjects from U.S. and Europe, including antibiotic resistant strains. Currently, the drug is being developed in the Phase I/II stage of clinical trial evaluation for the treatment of Atopic Dermatitis.

* LP 0145: LEO Pharma

LP 0145, is an anti-inflammatory monoclonal antibody under development for atopic dermatitis. Currently, the drug is being developed in the Phase II stage of clinical trial evaluation for the treatment of Eczemas.

The Eczema Pipeline Report Provides Insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of Eczema with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Eczema Treatment.
* Eczema Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Eczema Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Eczema market

Explore groundbreaking therapies and clinical trials in the Eczema Pipeline. Access DelveInsight's detailed report now! @ New Eczema Drugs [https://www.delveinsight.com/sample-request/eczema-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Eczema Companies

Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries, Brickell Biotech Inc., Dermira, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics , and others.

Eczema Pipeline Report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Intra-articular
* Intraocular
* Intrathecal
* Intravenous
* Ophthalmic
* Oral
* Parenteral
* Subcutaneous
* Topical
* Transdermal

Eczema Products have been categorized under various Molecule types such as

* Oligonucleotide
* Peptide
* Small molecule

Unveil the future of Eczema Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Eczema Market Drivers and Barriers [https://www.delveinsight.com/sample-request/eczema-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Eczema Pipeline Report

* Coverage- Global
* Eczema Companies- Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries, Brickell Biotech Inc., Dermira, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics , and others.
* Eczema Pipeline Therapies- alitretinoin, Arctiva, KY1005, Dupilumab, Lebrikizumab, Baricitinib, MEDI9929, Midazolam, Omeprazole , and others.
* Eczema Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Eczema Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Eczema Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Eczema Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/eczema-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Contents

* Introduction
* Executive Summary
* Eczema: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Eczema- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Drug name : Company name
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Amlitelimab: Kymab
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Drug name : Company name
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name : Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Eczema Key Companies
* Eczema Key Products
* Eczema- Unmet Needs
* Eczema- Market Drivers and Barriers
* Eczema- Future Perspectives and Conclusion
* Eczema Analyst Views
* Eczema Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=eczema-pipeline-drugs-landscape-report-2025-moa-analysis-rd-progress-clinical-trial-pipeline-and-strategic-market-evolution]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/eczema-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.